CollPlant Biotechnologies Reports Q1 2024 Financial Results
Ticker: CLGN · Form: 6-K · Filed: May 29, 2024 · CIK: 1631487
Sentiment: neutral
Topics: financial-results, q1-2024, reporting
TL;DR
CollPlant dropped its Q1 2024 numbers, check the financials.
AI Summary
CollPlant Biotechnologies Ltd. filed a Form 6-K on May 29, 2024, reporting its first quarter financial results. The filing details the company's financial performance and operational updates for the period ending March 31, 2024. CollPlant is a regenerative medicine company focused on tissue engineering and 3D bioprinting.
Why It Matters
This filing provides investors with an update on CollPlant's financial health and operational progress in the first quarter of 2024, crucial for assessing the company's trajectory in the regenerative medicine sector.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- 001-38370 (company) — SEC File Number
- May 29, 2024 (date) — Filing Date
- March 31, 2024 (date) — Reporting Period End Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the first quarter financial results of CollPlant Biotechnologies Ltd. for the period ending March 31, 2024.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on May 29, 2024.
What is the SEC file number for CollPlant Biotechnologies Ltd.?
The SEC file number for CollPlant Biotechnologies Ltd. is 001-38370.
What is the company's principal executive office address?
The company's principal executive office is located at 4 Oppenheimer St, Weizmann Science Park, Rehovot 7670104, Israel.
Does CollPlant Biotechnologies Ltd. file annual reports under Form 20-F or Form 40-F?
CollPlant Biotechnologies Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 283 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-05-29 07:07:29
Filing Documents
- ea0206970-6k_collpla.htm (6-K) — 11KB
- ea020697001ex99-1_collplant.htm (EX-99.1) — 106KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-047246.txt ( ) — 137KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: May 29, 2024 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2